Search the Newsreel

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue Estimates

BioXcel Therapeutics (BTAI) reported a Q2 loss of $0.49 per share, beating the Zacks Consensus Estimate of a $0.51 loss, but missed revenue estimates with $0.18 million, 46.47% below consensus. Despite an earnings surprise this quarter and last, the company's shares have fallen 33.8% …

BioXcel Therapeutics (BTAI) flags going concern risk with high debt and cash strain

BioXcel Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against BioXcel Therapeutics, Inc. (NASDAQ: BTAI) and reminds investors of the September 5, 2023, deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit stems from allegations that BioXcel made …

BioXcel Therapeutics Amends Oaktree Credit Pact, Extends Deal Deadline and Lowers Liquidity Floor

BioXcel Therapeutics has amended its credit agreement with Oaktree, extending the deadline to secure refinancing or alternative capital to August 21, 2026. The amendment also reduces the minimum liquidity covenant from $6.25 million to $3.0 million, providing the company with more time and financial …

BioXcel Therapeutics (BTAI) cuts liquidity covenant, faces August 2026 refinancing deadline

BioXcel Therapeutics (BTAI) has amended its Credit Agreement, extending its refinancing deadline to August 21, 2026, and reducing its minimum liquidity covenant from $6.25 million to $3.0 million. This amendment gives the company more time to secure financing or strategic options and eases its …

Bioceres Crop Solutions (BIOX) CEO reports 130,000-share bona fide gift via trust

Bioceres Crop Solutions CEO Federico Trucco reported a bona fide gift of 130,000 Ordinary Shares transferred via the Testamentario MQT Trust for the benefit of his child on May 20, 2026. Following this transaction, he disclaims beneficial ownership of these shares except for any …

Bioceres Crop Solutions raises $42.5 Mn to accelerate the launch of HB4 technology

Bioceres Crop Solutions has successfully raised $42.5 million through secured convertible promissory notes to expedite the launch of its HB4 technology. This innovative seed solution offers drought and salinity tolerance for soybean and wheat crops. The funding will enable the company to significantly expand …

BTAI News | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI)

BTAI Q2'26 Earnings: EPS estimate is (0.44) USD

BioXcel Therapeutics, Inc. (BTAI) is expected to announce its Q2'26 earnings on August 11, with an estimated revenue of 484.63 thousand USD and an EPS of (0.44) USD. The article provides a table of historical and estimated revenue and EPS figures, along with surprise …

Bioceres Crop Solutions Corp. Revenue Breakdown – NASDAQ:BIOX

Bioceres Crop Solutions Corp. (NASDAQ: BIOX) generated 335.30 million USD in revenue last year. The Crop Protection segment was the top-performing segment, contributing 181.91 million USD. Geographically, Argentina was the largest contributor to revenue, accounting for 231.55 million USD.

Bioceres Crop Solutions Corp (BIOX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Bioceres Crop Solutions Corp (BIOX), highlighting that no earnings forecast score is currently available, but the chemicals industry average is 7.36. Analysts project a target price of $5.00 for BIOX, with a high of $5.00 and a …

Bioceres Crop Solutions Corp (BIOX) Stock News Today

This page provides the latest news and developments for Bioceres Crop Solutions Corp (BIOX) stock. It includes current stock price information, market capitalization, and a note indicating that more news is coming soon. The page serves as a hub for investors to track BIOX's …

BioXcel Therapeutics Inc (BTAI) Earnings Forecast: Future EPS & Revenue Growth Estimates

Bioceres Crop Solutions (NASDAQ: BIOX) CEO logs 150,000-share equity gift

Bioceres Crop Solutions CEO Federico Trucco reported a bona fide gift transfer of 150,000 Ordinary Shares on May 20, 2026. These shares are held indirectly through Testamentario MQT Trust for the benefit of his child, with Trucco disclaiming beneficial ownership except for pecuniary interest. …

Bioceres Crop Solutions (BIOX) grants CFO 375,000 options under 2023 equity plan

Bioceres Crop Solutions Corp. (BIOX) has granted its CFO, Ezequiel Simmermacher, 375,000 employee stock options under the 2023 Omnibus Equity Incentive Plan. These options, with an exercise price of $1.45 per share, will vest annually in three equal installments starting June 30, 2026, and …

BioXcel Shareholder Notice

Faruqi & Faruqi, LLP is investigating potential claims against BioXcel Therapeutics, Inc. (NASDAQ: BTAI) and encourages investors who lost over $100,000 to contact them before the September 5, 2023 deadline to seek lead plaintiff status. This investigation follows a significant stock drop after BioXcel …

BioXcel Therapeutics amends Oaktree-led credit agreement, defers loan payment to Aug. 31

BioXcel Therapeutics has amended its credit agreement with lenders led by Oaktree Fund Administration, deferring a loan payment of $9.02 million from July 31 to August 31, 2026. The company also saw its minimum liquidity covenant lowered to $6.25 million from $7.5 million. BioXcel …

BioXcel Therapeutics Wins Deferral on $9.0M Payment, Liquidity Covenant Cut to $6.25M Under Oaktree Deal

BioXcel Therapeutics (BTAI) has secured a deferral on a $9.0 million principal and interest payment with Oaktree until August 31, 2026, via the Eleventh Amendment to its Credit Agreement. This amendment also reduces the minimum liquidity covenant to $6.25 million. By August 10, 2026, …

BioXcel Shareholder Action Reminder

Faruqi & Faruqi, LLP is investigating potential claims against BioXcel Therapeutics, Inc. (NASDAQ: BTAI) and reminds investors of the September 5, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. This action follows BioXcel's disclosure that a principal …

Why Is Bioxyne (ASX:BXN) Back In Wellness Debate?

Bioceres Crop Solutions Corp (BIOX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Bioceres Crop Solutions Corp (BIOX), highlighting its current valuation score and P/E ratio. The company's valuation score is 7.21, ranking it 45th in the Chemicals industry. It notes that key P/E, P/B, P/S, and P/CF data have …

BioXcel Therapeutics Inc (BTAI) Institutional Confidence

This article from TradingKey provides an overview of BioXcel Therapeutics Inc (BTAI)'s institutional confidence, based on an updated score of 3.00 as of July 28, 2026. It details the shares held by various institutional investors and Star Investors, along with the percentage change in …

BioXcel Therapeutics Inc (BTAI) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of BioXcel Therapeutics Inc (BTAI), highlighting its current valuation score of 8.84 within the Pharmaceuticals industry. It also details the company's P/E ratio, noting that other relevant financial data such as P/B, P/S, and P/CF have not yet …

Bioceres Crop Solutions Corp (BIOX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Bioceres Crop Solutions Corp (BIOX), ranking it 59 out of 65 in the Chemicals industry with a score of 1.99. It details the company's beta of 0.38, indicating underperformance in rising markets but smaller declines in falling …

Bioceres Crop Solutions Corp (BIOX) Institutional Confidence

The institutional confidence score for Bioceres Crop Solutions Corp (BIOX) is 3.00, placing it 50th out of 65 in the Chemicals industry. Institutional shareholding declined by 15.96% quarter-over-quarter to 31.92%. Bill Nygren | OAKMX is the largest institutional shareholder, holding 0.01% of outstanding shares.

BTAI|BioXcel Therapeutics Inc|Price:0.845|Chg%:-0.022

This article provides a comprehensive stock analysis of BioXcel Therapeutics Inc (BTAI), highlighting its relatively stable fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. The company is actively developing neuroscience and immuno-oncology candidates, with analysts predominantly rating it as a "Buy" …

BioXcel Therapeutics Inc (BTAI) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of BioXcel Therapeutics Inc's (BTAI) dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. The article also details several merger-related stock splits scheduled for February 6, 2025, each …

BioXcel Therapeutics Inc (BTAI) Income Statement

This article provides an income statement for BioXcel Therapeutics Inc (BTAI), presenting detailed quarterly and annual financial data spanning several years. It includes key metrics such as total revenue, operating expenses, R&D expenses, operating profit, and net income, alongside basic and diluted earnings per …

BioXcel Therapeutics, Inc. Revenue Breakdown – MUN:BX20

BioXcel Therapeutics, Inc. (MUN:BX20) generated 546.61K EUR in revenue last year, primarily from its Medicines segment, a decrease from 2.19M EUR in the previous year. The United States was the company's largest contributor to revenue, accounting for the entire 546.61K EUR.

Bioceres Crop Solutions Corp (BIOX) Income Statement

This article provides the quarterly and annual income statements for Bioceres Crop Solutions Corp (BIOX), offering detailed financial data such as total revenue, operating expenses, net income, and earnings per share. It also includes an FAQ section explaining how to interpret income statements and …

Bioceres Crop Solutions Corp (BIOX) Balance Sheet

This article provides the quarterly and annual balance sheets for Bioceres Crop Solutions Corp (BIOX), detailing assets, liabilities, and shareholders' equity. It includes financial data such as cash, receivables, inventory, and debt figures across various fiscal quarters. The content also features an FAQ section …

BIOX|Bioceres Crop Solutions Corp|Price:0.343|Chg%:-0.005

This article provides a detailed financial overview of Bioceres Crop Solutions Corp (BIOX), including its latest stock price, market cap, and key financial statements. It presents quarterly and annual data for revenue, EPS, net profit, margins, debt-to-asset ratio, and cash flow, accessible via an …

Bioceres Crop Solutions Corp (BIOX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Bioceres Crop Solutions Corp (BIOX) stock information, including its current market price, market capitalization, and P/E TTM. It specifically highlights the company's dividend history, noting that no dividend data is currently available and that $0.00 has been distributed …